Press Releases

Since co-founding twoXAR five years ago, I have consistently held the same beliefs about AI’s role in drug discovery, and I’ve delivered a consistent message about it. The world’s reaction to my words has evolved, from skepticism to curiosity to full-blown excitement.

Many believe AI is the panacea that will revolutionize the healthcare industry, and dollars are flowing into healthcare AI startups at unprecedented rates as investors make big bets on using the technology to analyze health data, improve efficiency in healthcare delivery, speed drug discovery, and offer new therapies for intractable diseases... read post here.

Five years ago my namefellow, Andrew A. Radin (twoXAR CEO), and I launched twoXAR to apply new technology to discovering medicines for patients with unmet medical needs. Over the years we developed our 3P strategy (platform, process, portfolio) which I am confident is the most efficient, lowest risk, and highest probability path to success in today’s world of drug development.

After careful consideration and planning I’ve decided now is the right time for me to transition to an advisory role at twoXAR. To implement the 3P strategy we’ve built an exceptional team of scientists, engineers, and business professionals that continues to develop and broaden month over month. I am consistently impressed by our team’s expertise, capabilities, and accomplishments — it’s their commitment and dedication that propels forward our mission... read post here.

This week I had the pleasure to sign an R&D collaboration agreement with SK Biopharmaceuticals, our new friends at in South Korea’s Pangyo Techno Valley.

In the last several months, SKBP has achieved several remarkable drug development milestones, including the first FDA approval of an SKBP-discovered drug (Sunosi™, for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, which has been licensed to Jazz Pharmaceuticals) and FDA acceptance of their NDA submission for cenobamate, an investigational antiepileptic drug. With this recent progress, SKBP is quickly emerging as the leading end-to-end pharmaceutical company in South Korea... read post here.

I'm pleased to announce that we have signed our second partnership deal of 2019; this time in a (undisclosed) neurological disease with Ono Pharmaceutical.

Ono recently celebrated their 300th anniversary of delivering medications to patients in need. When I visited their research headquarters in Osaka, Japan I was impressed by the exposition in their lobby chronicling their rich history. I was reminded of the evolution of the industry and of twoXAR itself... read post here.

Having devoted my professional life to the discovery and development of novel therapies to tackle life-threatening diseases, including drug-resistant forms of cancer, I am thrilled to be working with an innovative discovery approach for the treatment of glioblastoma.

Glioblastoma multiforme is the most common and deadly form of brain cancer globally. It aggressively invades brain tissue and causes rapid onset of neurological symptoms. This invasion includes fostering a highly vascularized microenvironment and intricate interactions between tumor and non-tumor cells within the brain which promotes its growth and survival despite current treatments... read post here.

Pancreatic cancer is a terrible disease. The most common form, pancreatic ductal adenocarcinoma (PDAC), has a grim prognosis and the efficacy of existing and experimental treatments leaves much to be desired. Toward addressing the need for new therapies, we are announcing... read post here.

twoXAR Co-Founder, Andrew M. Radin, discusses Recent IP and Business Trends in Advanced Drug Discovery Technology panel with Ichiro Nakatomi, S. Roy Kimura, Patrick Reid, Rob Garbaccio.

twoXAR Co-Founder, Andrew M. Radin, discusses the applications of AI in Drug Discovery.

twoXAR CEO, Andrew A. Radin, discusses the applications of AI in Drug Discovery.

Meet twoXAR and other technology-driven life science and healthcare companies for networking, recruiting, and more.

twoXAR Co-Founder, Andrew M. Radin, discusses artificial intelligence in drug discovery.

twoXAR CEO, Andrew A. Radin, discusses artificial intelligence in drug discovery and how it's impacting the discovery of novel ophthalmology therapeutics.

twoXAR CEO, Andrew A. Radin, speaks about the Applications of AI in Drug Discovery

twoXAR CEO, Andrew A. Radin, speaks with Harry Glorikian of the Moneyball Medicine Podcast.

twoXAR CEO, Andrew A. Radin, is joined by GSK's John Baldoni & Nimbus's Mark Ashwell.

twoXAR CEO, Andrew A. Radin, presents What if new medications could be found in minutes instead of years?

twoXAR CEO, Andrew A. Radin, is joined by Jeff Kindler & Vijay Pande.